scholarly journals The effects of steamed ginger ethanolic extract on weight and body fat loss: a randomized, double-blind, placebo-controlled clinical trial

2019 ◽  
Vol 29 (2) ◽  
pp. 265-273 ◽  
Author(s):  
Soo-Hyun Park ◽  
Su-Jin Jung ◽  
Eun-Kyung Choi ◽  
Ki-Chan Ha ◽  
Hyang-Im Baek ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Body Mass Index ◽  
Body Weight ◽  
Body Mass ◽  
Body Fat ◽  
Ethanolic Extract ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Fat Loss

Abstract Steamed ginger ethanolic extract (SGE) is a product with a high 6-shogaol contents and is thought to be more potent than other ginger products. We conducted a 12-week, randomized, double-blind, placebo-controlled clinical trial to determine the effects of SGE on weight and body fat loss. Eighty healthy obese participants were recruited and randomly divided into the SGE and placebo groups. The outcome measures comprised indicators of efficacy (body weight, body mass index, body composition, and blood markers) and safety. Following the supplementation period, mean body weight, body mass index, and body fat level were significantly lower in the SGE group than in the placebo group. No clinically significant changes were observed for any safety parameter. These results suggest that SGE is a potent anti-obesity agent that does not cause significant side effects. Therefore, SGE supplementation combined with lifestyle modification could be effective in the management of body weight and fat mass.

scholarly journals The Effects of Aronia Extract on Body Weight and Body Fat: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

2020 ◽  
Vol 30 (1) ◽  
pp. 105-113
Author(s):  
Ki Chan Ha ◽  
Yu Kyung Park ◽  
Hyang Im Baek ◽  
Hye Mi Kim ◽  
Young Mi Kim ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Body Weight ◽  
Body Fat ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Seaweed Fucoxanthin Supplementation Improves Obesity Parameters in Mild Obese Japanese Subjects

2017 ◽  
Vol 7 (4) ◽  
pp. 246 ◽  
Author(s):  
Shoketsu Hitoe ◽  
Hiroshi Shimoda
Keyword(s):  
Body Mass Index ◽  
Body Weight ◽  
Placebo Group ◽  
Body Mass ◽  
Subcutaneous Fat ◽  
Abdominal Fat ◽  
Thigh Circumference ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Obese Subjects

Background: Fucoxanthin is a seaweed xanthophyll that has demonstrated an anti-obesity effect in rodents. However, clinical investigations of its influence on mildly obese subjects has not been performed. We conducted a clinical trial of fucoxanthin supplementation in Japanese obese subjects. Methods: We examined the effect of fucoxanthin (1 or 3 mg daily) in a double-blind placebo-controlled study. Capsules containing fucoxanthin or placebo capsules were administered for 4 weeks to male and female Japanese adults with a body mass index (BMI) of more than 25 kg/m2. Before and after treatment, the body weight, body composition, abdominal fat area, and the circumferences of the neck, arm, and thigh were evaluated.Results: There was significant reduction of the relative (ratio versus before treatment) body weight, BMI, and visceral fat area in the 3 mg/day fucoxanthin group compared to the placebo group. Relative values of total fat mass, subcutaneous fat area, waist circumference, and right thigh circumference were also significantly lower in the 1 mg/day fucoxanthin group than the placebo group. A significant decrease of the absolute right thigh circumference was noted in the 1 mg/day fucoxanthin group compared to the placebo group. In the subjects ingesting fucoxanthin, there were no abnormalities of the blood pressure, pulse rate, blood parameters, and urinalysis parameters, which thereby suggests adverse effects. Conclusions: Fucoxanthin reduced body weight, BMI, and abdominal fat by acting on both visceral and subcutaneous fat. Consequently, Fucoxanthin may be able to improve a moderate overweight state in both men and women. Keywords: Randomized, double-blind, placebo-controlled crossover trial; fucoxanthin; body mass index; body weight; subcutaneous fat; adipose tissue

Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial

Maturitas ◽  
2005 ◽  
Vol 51 (4) ◽  
pp. 397-404 ◽  
Author(s):  
S. Frei-Kleiner ◽  
W. Schaffner ◽  
V.W. Rahlfs ◽  
Ch. Bodmer ◽  
M. Birkhäuser
Keyword(s):  
Clinical Trial ◽  
Ethanolic Extract ◽  
Controlled Clinical Trial ◽  
Cimicifuga Racemosa ◽  
Double Blind ◽  
Double Blind Placebo

Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients with Prediabetes

2018 ◽  
Vol 128 (08) ◽  
pp. 506-511 ◽  
Author(s):  
Alejandra M. Ramírez-Rodríguez ◽  
Manuel González-Ortiz ◽  
Esperanza Martínez-Abundis
Keyword(s):  
Body Mass Index ◽  
Body Weight ◽  
Uric Acid ◽  
Insulin Secretion ◽  
Insulin Sensitivity ◽  
Waist Circumference ◽  
Body Mass ◽  
Fasting Glucose ◽  
Controlled Clinical Trial ◽  
Double Blind

Abstract Aim To evaluate the effect of dapagliflozin on insulin secretion and insulin sensitivity in patients with prediabetes. Methods A randomized, double-blind, placebo-controlled clinical trial was carried out in 24 adults diagnosed with prediabetes and without pharmacological treatment. Patients were randomly assigned into two groups of 12 patients each to receive 10 mg of oral dapagliflozin or placebo once a day during 12 weeks. At baseline and at the end of the study, anthropometric and metabolic measurements were evaluated, including the first phase of insulin secretion, total insulin secretion, and insulin sensitivity. Results After dapagliflozin administration, there were significant decreases in body weight (80.8±16.3 vs. 77.8±14.9 kg, p=0.019), body mass index (30.3±3.5 vs. 29.2±3.1 kg/m2, p=0.023), waist circumference (100.6±13.5 vs. 96.2±11.8 cm, p=0.003), fasting glucose (5.9±0.4 vs. 5.1±0.3 mmol/L, p<0.001) and uric acid (334.3±70.8 vs. 262.9±60.7 mmol/L, p=0.032), with a tendency to increase the insulin sensitivity (1.94±0.72 vs. 2.63±1.04, p=0.064). Conclusion Dapagliflozin administration in patients with prediabetes decreased body weight, body mass index, waist circumference, fasting glucose, and uric acid, with a tendency to increase the insulin sensitivity without changes in insulin secretion.

Double blind placebo controlled clinical trial of homoeopathic medicines in HIV infection

1998 ◽  
Vol 87 (2) ◽  
pp. 86-88
Author(s):  
D P Rastogi ◽  
V P Singh ◽  
Vikram Singh ◽  
S K Dey ◽  
K Rao
Keyword(s):  
Clinical Trial ◽  
Hiv Infection ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document